Detalhe da pesquisa
1.
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).
Am Heart J
; 213: 97-104, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31132584
2.
Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.
CPT Pharmacometrics Syst Pharmacol
; 11(8): 1111-1121, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665486
3.
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.
J Clin Pharmacol
; 62(2): 220-231, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34524700